Skip to main content
Clinical Trials/NCT04906824
NCT04906824
Active, not recruiting
Not Applicable

Post-Market Registry in Europe and US for the Use of VascuCelTM

LeMaitre Vascular5 sites in 2 countries100 target enrollmentJune 9, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Great Vessel Reconstruction
Sponsor
LeMaitre Vascular
Enrollment
100
Locations
5
Primary Endpoint
Incidence of graft related reintervention
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

This is a post-market, multi-centre, open-label registry designed to collect prospective safety and performance data on the use of VascuCel in patients who require great vessel reconstruction, peripheral vascular reconstruction or suture line buttressing. This registry will collect safety and performance data up to 2 years following implantation.

Detailed Description

Post-market, prospective, multi-centre, open-label, registry designed to collect prospective safety and performance data on the use of VascuCel in patients with vascular disorders and in accordance with local standard of care. The Registry has been designed to collect data up to 2 years following implantation. The VascuCel Registry will collect data on the use of the VascuCel, for the following major indications: * Great vessel reconstruction * Peripheral vascular reconstruction As suture line buttressing is a procedure that does not consistently use tissue, data on this indication will only be included if available. Data will be prospectively collected by the sites on registry-specific electronic case report forms (eCRFs). The primary endpoints will assess device's safety and performance through measures and images obtained via the facility's standard of care at the respective registry site. Additional data will also be collected from the implant procedure to assess user (surgeon) satisfaction with the devices' handling and performance.

Registry
clinicaltrials.gov
Start Date
June 9, 2023
End Date
September 2026
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • patient has signed the informed consent
  • patient is a candidate for treatment with VascuCel per approved device indications.

Exclusion Criteria

  • no study specific exclusion criteria; patients treated per standard clinical practice

Outcomes

Primary Outcomes

Incidence of graft related reintervention

Time Frame: 30 days post procedure.

collect data on the number of incidence of graft related reintervention

Incidence of patch related morbidity

Time Frame: 30 days post procedure.

collect data on patch related morbidity

Secondary Outcomes

  • incidence of unanticipated and rare events(at 30 days and 1 and 2 years follow-up)
  • incidence of Patch retraction(at 30 days and 1 and 2 years follow-up)
  • incidence of Patch dehiscence(at 30 days and 1 and 2 years follow-up)
  • Incidence of graft related reintervention(at 1 and 2 years post procedure.)
  • Rates of restenosis(at 30 days and 1 and 2 years follow-up)
  • incidence of Patch calcification(at 30 days and 1 and 2 years follow-up)
  • Rates of measurement of the dynamic flow by facility standard of care ≥110-175* cm/sec for peripheral vascular location(at 30 days and 1 and 2 years follow-up)

Study Sites (5)

Loading locations...

Similar Trials